Uncategorized

Webinar: Streamlining Nonclinical Development with FDA NAMs

Published

on

FDA’s draft guidance on the validation of non-animal methods (NAMs) is reshaping how nonclinical programs are designed and justified. This webinar explores how sponsors can apply NAMs to streamline development, improve human relevance, and support IND decision-making within a weight-of-evidence framework.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version